$14.19
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Overview
52-week range
$11
$17
54% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
-0.2%
0% positive
Latest IV / EM
4826%
EM ±754.1% · $20 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.18 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-0.97 | — | — | — | -0.2% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-0.75 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-0.44 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | $3M | $20M | — | $4M | $2M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-23M | $-17M | — | $-13M | $-7M |
| Net income | $-20M | $-17M | — | $-13M | $-7M |
| EPS (diluted) | $-1.18 | $-0.97 | — | $-0.75 | $-0.44 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $72M | $268M | $0 | $0 | $0 |
| Inventory | — | — | — | — | — |
| Total current assets | $275M | $286M | $3M | — | — |
| Total assets | $281M | $292M | $8M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $66M | $58M | $71M | — | — |
| Total equity | $215M | $234M | $-63M | $-56M | $-56M |